U.S. markets open in 7 hours 27 minutes
  • S&P Futures

    3,858.75
    +10.50 (+0.27%)
     
  • Dow Futures

    31,094.00
    +81.00 (+0.26%)
     
  • Nasdaq Futures

    11,925.00
    +44.75 (+0.38%)
     
  • Russell 2000 Futures

    1,735.00
    +6.40 (+0.37%)
     
  • Crude Oil

    98.91
    +0.38 (+0.39%)
     
  • Gold

    1,745.30
    +8.80 (+0.51%)
     
  • Silver

    19.25
    +0.16 (+0.84%)
     
  • EUR/USD

    1.0210
    +0.0026 (+0.26%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.73
    -0.81 (-2.94%)
     
  • GBP/USD

    1.1948
    +0.0026 (+0.22%)
     
  • USD/JPY

    135.8280
    -0.0870 (-0.06%)
     
  • BTC-USD

    20,304.18
    +262.85 (+1.31%)
     
  • CMC Crypto 200

    441.56
    +6.04 (+1.39%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,427.87
    +320.22 (+1.23%)
     

We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash Wisely

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

Given this risk, we thought we'd take a look at whether Talaris Therapeutics (NASDAQ:TALS) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

View our latest analysis for Talaris Therapeutics

How Long Is Talaris Therapeutics' Cash Runway?

You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. As at September 2021, Talaris Therapeutics had cash of US$255m and no debt. Importantly, its cash burn was US$37m over the trailing twelve months. So it had a cash runway of about 6.8 years from September 2021. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Talaris Therapeutics' Cash Burn Changing Over Time?

Because Talaris Therapeutics isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by a very significant 87%. Oftentimes, increased cash burn simply means a company is accelerating its business development, but one should always be mindful that this causes the cash runway to shrink. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

Can Talaris Therapeutics Raise More Cash Easily?

Given its cash burn trajectory, Talaris Therapeutics shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

Since it has a market capitalisation of US$397m, Talaris Therapeutics' US$37m in cash burn equates to about 9.4% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About Talaris Therapeutics' Cash Burn?

It may already be apparent to you that we're relatively comfortable with the way Talaris Therapeutics is burning through its cash. For example, we think its cash runway suggests that the company is on a good path. Although we do find its increasing cash burn to be a bit of a negative, once we consider the other metrics mentioned in this article together, the overall picture is one we are comfortable with. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, Talaris Therapeutics has 4 warning signs (and 2 which are a bit concerning) we think you should know about.

Of course Talaris Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.